Advantage of Insulin Glulisine Over Regular Insulin in Patients With Type 2 Diabetes and Severe Renal Insufficiency

Journal of Renal Nutrition

Volumn 25, Issue 2, 2015, Pages 129-134

  Urata, Hiromi ^a   Mori, Katsuhito ^a   Emoto, Masanori ^a   Yamazaki, Yuko ^a   Motoyama, Koka ^a   Morioka, Tomoaki ^a   Fukumoto, Shinya ^a   Koyama, Hidenori ^b   Shoji, Tetsuo ^a   Ishimura, Eiji ^a   Inaba, Masaaki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN; INSULIN GLULISINE;

ANALOGS AND DERIVATIVES; COMPLICATION; DIABETES MELLITUS, TYPE 2; FEMALE; HUMAN; KIDNEY FAILURE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; TREATMENT OUTCOME;

EID: 84925144283     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2014.07.011     Document Type: Article

References (21)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329:977-986.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853.
3. Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
4. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
5. Patel A., MacMahon S., Chalmers J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
6. Morioka T., Emoto M., Tabata T., et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 2001, 24:909-913.
7. Oomichi T., Emoto M., Tabata T., et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care 2006, 29:1496-1500.
8. Ramirez S.P., McCullough K.P., Thumma J.R., et al. Hemoglobin A(1c) levels and mortality in the diabetic hemodialysis population: findings from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Diabetes Care 2012, 35:2527-2532.
9. Ricks J., Molnar M.Z., Kovesdy C.P., et al. Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: a 6-year cohort study. Diabetes 2012, 61:708-715.
10. Shurraw S., Hemmelgarn B., Lin M., et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med 2011, 171:1920-1927.
11. Iglesias P., Diez J.J. Insulin therapy in renal disease. Diabetes Obes Metab 2008, 10:811-823.
12. Moen M.F., Zhan M., Hsu V.D., et al. Frequency of hypoglycemia and itssignificance in chronic kidney disease. Clin J Am Soc Nephrol 2009, 4:1121-1127.
13. Garg R., Williams M.E. Diabetes management in the kidney patient. Med Clin North Am 2013, 97:135-156.
14. Seaquist E.R., Anderson J., Childs B., et al. Hypoglycemia and diabetes: a report of a workgroup of the American diabetes association and the endocrine society. Diabetes Care 2013, 36:1384-1395.
15. Heise T., Nosek L., Spitzer H., et al. Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes Metab 2007, 9:746-753.
16. Bolli G.B., Luzio S., Marzotti S., et al. Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. Diabetes Obes Metab 2011, 13:251-257.
17. Imai E., Horio M., Nitta K., et al. Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan. Am J Kidney Dis 2007, 50:927-937.
18. Service F.J., Molnar G.D., Rosevear J.W., et al. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970, 19:644-655.
19. Biesenbach G., Raml A., Schmekal B., et al. Decreased insulin requirement in relation to GFR in nephropathic Type 1 and insulin-treated Type 2 diabetic patients. Diabet Med 2003, 20:642-645.
20. Rave K., Heise T., Pfutzner A., et al. Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care 2001, 24:886-890.
21. Aisenpreis U., Pfutzner A., Giehl M., et al. Pharmacokinetics and pharmacodynamics of insulin Lispro compared with regular insulin in haemodialysis patients with diabetes mellitus. Nephrol Dial Transplant 1999, 4(suppl 14):5-6.